Sweden's Acarix Q4 revenue rises 26%, driven by U.S. demand

Acarix AB

12/02/2026 07:14

Overview

Swedish cardiac diagnostics firm's Q4 revenue grew 26% yr/yr

Operating costs fell 23%, improving net loss by 27%

U.S. patch sales rose 73% in Q4

Outlook

Company focuses on converting reimbursement momentum into higher utilization and recurring revenue

Acarix aims to scale sustainably with expanding access in Europe and the U.S.

Result Drivers

SYSTEM DELIVERIES - Acarix delivered 23 CADScor Systems in Q4, a 64% increase, with 19 sold in the U.S., boosting revenue growth

U.S. MARKET GROWTH - U.S. revenue rose 87% in Q4, driven by increased system placements and patch sales

COST REDUCTION - Operating costs decreased by 23%, aiding a 27% improvement in net loss

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
SEK 2.14 mln
Q4 EPS
-SEK 0.01
Q4 Gross Margin
83.00%


Analyst Coverage

Wall Street's median 12-month price target for Acarix AB is SEK0.40, about 29.7% above its February 11 closing price of SEK0.31

Press Release: ID:nMFN3YcgdT

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)